Zobrazeno 1 - 10
of 40
pro vyhledávání: '"A I Savelyeva"'
Publikováno v:
Гинекология, Vol 26, Iss 1, Pp 95-101 (2024)
Background. Side effects of endocrine therapy with tamoxifen (TAM) reduce the quality of life of patients with breast cancer (BC) and adversely affect treatment compliance. Against the background of treatment of BC with TAM, the risk of developing en
Externí odkaz:
https://doaj.org/article/6c76856237134f8286cf525344391292
Autor:
G. A. Radzhabova, T. T. Valiev, Yu. E. Ryabukhina, M. I. Savelyeva, Sh. P. Abdullaev, O. D. Gurieva, P. A. Zeynalova
Publikováno v:
Онкогематология, Vol 19, Iss 2, Pp 26-33 (2024)
Background. A significant advancement in the treatment of high-grade aggressive non-Hodgkin’s lymphomas and acute lymphoblastic leukemia is the inclusion of high-dose (1000–5000 mg/m2) methotrexate in the treatment protocol. This approach has sig
Externí odkaz:
https://doaj.org/article/7ff3050d35fa480b91ee3f5d75d2f1bc
Publikováno v:
Омский научный вестник: Серия "Авиационно-ракетное и энергетическое машиностроение", Vol 7, Iss 3, Pp 36-45 (2023)
The introduction of low–waste and waste–free technologies is an actual development direction for oil and gas enterprises, in particular for oil refineries. Development of methodological approaches to the analysis and synthesis of complex energy
Externí odkaz:
https://doaj.org/article/aba80d3f4e4348bd952c9735b08d367b
Publikováno v:
Consilium Medicum, Vol 25, Iss 8, Pp 497-504 (2023)
One of the main problems in pediatrics and pediatric oncology is early diagnosis of malignancies in children. It makes a provision for high surveillance more than 90% and ability to restrict an anti-cancer treatment, which define a high quality of li
Externí odkaz:
https://doaj.org/article/8327fd920cd2480490d84a3a80211e9c
Publikováno v:
Современная онкология, Vol 25, Iss 1, Pp 63-67 (2023)
Background. One of the main stages of the treatment of breast cancer (BC) is endocrine therapy with tamoxifen or aromatase inhibitors. Five years of adjuvant tamoxifen therapy reduces the risk of disease recurrence by 39%. Tamoxifen was approved by t
Externí odkaz:
https://doaj.org/article/18ce10a47b3a47cc8fd57c25c9061ffd
Autor:
Anna F. Pupysheva, Ekaterina I. Savelyeva, Valentina V. Piskunova, Anna A. Lenyushkina, Irina V. Nikitina, Olga D. Goncharuk, Olga A. Krogh-Jensen
Publikováno v:
Педиатрическая фармакология, Vol 20, Iss 1, Pp 51-55 (2023)
Background. Necrotizing enterocolitis (NEC) is severe gastrointestinal disease in newborns, its early clinical symptoms are nonspecific. Fecal сalprotectin (Cp) is considered as one of the early biomarkers of NEC, thus, its use in newborns is poorly
Externí odkaz:
https://doaj.org/article/f3773e0702fe46aa8e1bd9da8f59e9a1
Autor:
Marina I. Savelyeva, Ekaterina O. Golubenko, Zhannet A. Sozaeva, Irina V. Poddubnaya, Vera V. Korennaya
Publikováno v:
Современная онкология, Vol 24, Iss 3, Pp 361-367 (2022)
Background. Tamoxifen is the drug of choice in ER-positive breast cancer (BC) therapy for perimenopausal women and one of the endocrine therapy options for menopausal patients. The pharmacological effect of tamoxifen can be influenced by the activity
Externí odkaz:
https://doaj.org/article/2bd5d638878644ab93ae7e44df03de19
Autor:
Marina I Savelyeva, Irina A Dudina, Juliya S Zaharenkova, Anna K Ignatova, Kristina A Ryzhikova, Zhannet A Sozaeva, Dmitriy A Kudlay, Oksana M Perfileva, Irina V Poddubnaya
Publikováno v:
Современная онкология, Vol 21, Iss 1, Pp 24-30 (2019)
Tamoxifen is the selective modulator of estrogen receptors. Nowadays, it is widely used for treatment of premenopausal women with ER(+) breast cancer likewise for postmenopausal women with treatment contraindications to aromatase inhibitors. Tamoxife
Externí odkaz:
https://doaj.org/article/d4bdc1d67d384dca89823e5bd615a85f
Publikováno v:
Pharmacogenetics and Pharmacogenomics. :63-73
Relevance. Endocrine therapy is the standard treatment for women with ER-positive breast cancer. The clinical response to Tamoxifen is variable. Approximately 30 % of patients with breast cancer will have a recurrence of the disease within 15 years a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::7857deef7ea91d6012f3087183b117d2
https://doi.org/10.37489/2588-0527-2022-1-63-73
https://doi.org/10.37489/2588-0527-2022-1-63-73
Autor:
A. V. Degtyareva, E. I. Savelyeva, E. A. Filippova, A. A. Dokshukina, M. Kh. Isaeva, V. V. Zubkov, M. B. Albegova
Publikováno v:
Rossiyskiy Vestnik Perinatologii i Pediatrii (Russian Bulletin of Perinatology and Pediatrics). 67:123-130
Alagille syndrome is a genetic multisystem disease in which one of the key symptoms that significantly impairs quality of life is cholestatic pruritus. Until recently the only treatment opportunity was liver transplantation. In 2021 the new drug mara
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::f933996e218ecdae3a7898c391095544
https://doi.org/10.21508/1027-4065-2022-67-6-123-130
https://doi.org/10.21508/1027-4065-2022-67-6-123-130